Extracorporal modified ascitic fluid reinfusion in treatment of resistant ascites in liver cirrhosis
https://doi.org/10.24884/0042-4625-2017-176-3-32-37
Abstract
OBJECTIVE. The aim of the study was to estimate the efficacy of new method of reinfusion of extracorporeal modified ascitic fluid in therapy of diuretic resistance ascites in patients with liver cirrhosis and portal hypertension syndrome. MATERIAL AND METHODS. An analysis of treatment was made in 83 patients, who underwent laparocentesis and ascitic fluid evacuation. The patients were divided into two groups. Laparocentesis and fractional evacuation of ascitic fluid were carried out for the patients of the first group (n=40). This procedure was followed by intravenous infusion of 25 % albumin (10 g of albumin on each 2 litres of removed fluid) in order to make up losses of protein. Laparocentesis and ascitic fluid evacuation with following extracorporal processing and reinfusion were performed for the second group of patients (n=43). RESULTS. There was noted an increase of day diuresis from (620,0 ± 110,0) ml to (2,2 ± 0,4) l compared with the first group from (780 ± 80) ml to (1,2 ± 0,5) l and rise of sodium excretion (132 ± 7) mmol/l compared with the first group - (120 ± 6) mmol/l. An average molecular peptide concentration was decreased in blood plasma to (0,254 ± 0,098) units in the second group and it counted (0,298 ± 0,045) units in the first group. CONCLUSIONS. Reinfusion of extracorporeal modified ascitic fluid was more effective than conventional correction of albumin level and electrolytes disturbances against a background of ascitic fluid evacuation.
About the Authors
I. E. Onnintsev
S. M. Kirov Military Medical Academy
Russian Federation
Russian Federation
S. Ya. Ivanusa
S. M. Kirov Military Medical Academy
Russian Federation
Russian Federation
A. V. Khokhlov
S. M. Kirov Military Medical Academy
Russian Federation
Russian Federation
A. A. Sokolov
S. M. Kirov Military Medical Academy
Russian Federation
Russian Federation
A. V. Yankovskiy
S. M. Kirov Military Medical Academy
Russian Federation
Russian Federation
References
1. Борисов А. Е., Андреев Г. Н., Ибадильдин А. С. и др. Реинфузия асцитической жидкости при циррозе печени // Эфферентная терапия. 1999. Т. 2, № 2. С. 36-41.
2. Ерамищанцев А. К., Лебезев В. М., Мусин Р. А. Хирургическое лечение резистентного асцита у больных с портальной гипертензией // Хирургия. 2003. № 4. С. 4-8.
3. Журавлев В. А., Сухоруков В. П., Шишкин Б. А. Реинфузия асцитической жидкости при лечении асцитов у больных циррозом печени // Советская медицина. 1993. № 2. С. 95-97.
4. Зубарев П. Н. Реинфузия асцитической жидкости и аутокрови у больных циррозом печени // Материалы 4-й научной конференции ученых академии. 1987. С. 107-108.
5. Короткий В. Н., Покрасен Н. М., Гаевская В. А., Ляхов Н. П. Роль «средних молекул» в возникновении гипертермической реакции при реинфузии асцитической жидкости больным с циррозом печени // Клиническая хирургия 1999. № 9. С. 62.
6. Лебезев В. М., Мусин Р. А., Чуб Р. В., Краснова Т. Г. Хирургическое лечение диуретикорезистентного асцита у больных с портальной гипертензией // Анналы хирургической гепатологии. 2007. Т. 12, № 2. С. 22-25.
7. Хохлов А. В. Хирургическое лечение резистентного асцита у больных циррозом печени : Автореф. дис. … д-ра мед. наук. Л., 2005. 26 с.
8. Arroyo P., Ginеs J., Rodеs R., Schrier W. Malden Ascites and renal dysfunction in liver disease : pathogenesis, diagnosis, and treatment // Blackwell Science. 2005. Vol. 5, № 3. Р. 110-113.
9. Bernardi M., Gasbarrini A., Trevisani F. et al. Hemodynamic and renal effects of ascites apheresis, concentration and reinfusion in advanced cirrhosis // J. Hepatol. 1995. Vol. 22, № 1. P. 10-16.
10. Biggins S., Rodriguez H. J., Bass N. M. et al. Serum sodium predicts mortality in patients listed for liver transp lantation // Hepatology. 2005. Vol. 41. P. 32-39.
11. Bosch J., Berzigotti A., Garcia-Pagan J. C., Abraldes J. G. The management of portal hypertension: rational basis, available treatment and future options // J. Hepatol. 2008. Vol. 48. P. 68-93.
12. Cardenas A, Gines P. Management of refractory ascites // Clin. Gastroenterol. Hepatol. 2005. Vol. 3. P. 1187-1191.
13. Gerbes A. L., Gülberg V., Wiest R., Sauerbruch T. The mana gement of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis// J. Hepatol. 2010. P. 183-187.
14. Gluud L. L., Christensen K., Christensen E. et al. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome // Hepatology. 2010. Vol. 5, № 1. 1. P. 576-584.
15. Moreau R., Durand F., Poynard T. et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome : a retrospective multicenter study // Gastroenterology. 2002. Vol. 122. P. 923-930.
16. Neri S., Pulvirenti D., Malaguarnera M. et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome // Dig. Dis. Sci. 2008. Vol. 53. P. 830-835.
17. Rochling F.A., Zetterman R. K. Management of ascites // Drugs. 2009. Vol. 69, № 13. P. 1739-1760.
18. Yu A. S., Hu K. Q. Management of ascites // Clin. Liver. Dis. 2001. № 5. P. 541-568.
19. Zhou D. X., Zhou H. B., Wang Q. et al. The effectiveness of the treatment of octreotide on chylous ascites after liver cirrhosis // Dig. Dis. Sci. 2009. Vol. 54, № 8. P. 1783-1788.
Review
For citations:
Onnintsev I.E., Ivanusa S.Ya., Khokhlov A.V., Sokolov A.A., Yankovskiy A.V. Extracorporal modified ascitic fluid reinfusion in treatment of resistant ascites in liver cirrhosis. Grekov's Bulletin of Surgery. 2017;176(3):32-37. (In Russ.) https://doi.org/10.24884/0042-4625-2017-176-3-32-37
Views:
655
Email this article 